Opendata, web and dolomites

TheraSonix SIGNED

Ultrasonic Imaging and Drug Propulsion Into Tumors Using Genetically Encoded Gas Nanostructures

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TheraSonix project word cloud

Explore the words cloud of the TheraSonix project. It provides you a very rough idea of what is the project "TheraSonix" about.

cell    therapies    agents    position    attractive    circulation    nanoscale    drug    pharmacokinetic    filled    unlike    vastly    phenomenon    streaming    vesicles    maturity    overcoming    bubbles    re    microbubbles    diversify    inforce    microbes    microbubble    gvs    ultrasonic    overcome    gas    mass    layers    few    professional    therapeutics    match    drugs    anticancer    expand    deeper    dimensions    utilize    cellular    ultrasound    core    effect    time    collapse    physically    vasculature    nanostructures    prevents    concentrated    produces    selectivity    one    bind    constants    modern    limitation    vibration    limited    local    penetrating    buoyant    act    genetically    waves    combine    efficacy    advancements    penetration    stable    times    extravasate    imaging    enhanced    energy    conventional    shortcomings    therapeutic    heterogeneous    affordability    fluid    cavitation    influence    tumors    propels    class    hypothesize    encoded    engineering    protein    homing    tumor    photosynthetic    signal    tissues    nuclei    size   

Project "TheraSonix" data sheet

The following table provides information about the project.

Coordinator
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD 

Organization address
address: THE SENATE BUILDING TECHNION CITY 1
city: HAIFA
postcode: 32000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 263˙385 €
 EC max contribution 263˙385 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD IL (HAIFA) coordinator 263˙385.00
2    CALIFORNIA INSTITUTE OF TECHNOLOGYCORP US (PASADENA) partner 0.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

One of the important shortcomings of modern anticancer therapies is their limited penetration depth of only a few cell layers into the tumor. Concentrated around the heterogeneous vasculature, these drugs produce only a local therapeutic effect. In this project we propose a method of overcoming this limitation by engineering a novel class of gas-filled nanostructures capable of homing to tumor tissues, and using their vibration in response to ultrasound energy to deliver drugs deeper into the tumor core. The proposed approach is based on ultrasonic cavitation, a phenomenon in which gas bubbles expand and collapse under the influence of ultrasound waves. This process produces fluid streaming that propels drugs deeper into the tumor mass. The use of ultrasound for drug delivery is attractive due to its availability and affordability. However, the use of this technology is currently limited by the properties of conventional microbubble-based cavitation nuclei: their large size prevents them from penetrating into the tumor and their short circulation times do not match the pharmacokinetic time constants of many drugs. To overcome these challenges, we will utilize gas vesicles (GVs), a unique class of genetically encoded, gas-filled protein nanostructures derived from buoyant photosynthetic microbes, as cavitation nuclei. Unlike microbubbles, GVs are physically stable and their nanoscale dimensions have the potential to enable them to extravasate into tumors and bind to specific cellular targets. We hypothesize that GVs can act as both imaging agents and cavitation nuclei. If so, this therapeutic approach could have vastly improved efficacy and selectivity and the potential to combine cavitation-enhanced drug delivery with emerging advancements in cell based therapeutics. This project will enable the applicant to diversify his capabilities and experience beyond ultrasound imaging and signal processing and re-inforce a position of professional maturity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERASONIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERASONIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More